Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4813930 | 1.00 | ADORA2A (0.57) | ADORA2AADORA3ADORA2BCYP2C19SLC29A1 | |
| SCHEMBL217116 | 0.90 | CYP2C19 (0.60) | ADORA2AADORA3ADORA2BCYP2C19LMNA | |
| SCHEMBL7159063 | 0.90 | SLC29A1 (0.47) | ADORA2AADORA3ADORA2BCYP2C19SLC29A1 | |
| SCHEMBL7151768 | 0.89 | ADORA2A (0.46) | ADORA2AADORA3ADORA2BCYP2C19SLC29A1 | |
| SCHEMBL8930520 | 0.89 | ADORA2A (0.48) | ADORA2AADORA3ADORA2BCYP2C19SLC29A1 | |
| SCHEMBL7159475 | 0.89 | ADORA2A (0.46) | ADORA2AADORA3ADORA2BCYP2C19SLC29A1 | |
| SCHEMBL9347680 | 0.86 | ADORA2A (0.56) | ADORA2AADORA3ADORA2BCYP2C19SLC29A1 | |
| SCHEMBL27690308 | 0.85 | ADORA2A (0.60) | ADORA2AADORA3ADORA2BLMNANT5E | |
| SCHEMBL2208478 | 0.85 | ADORA2A (0.60) | ADORA2AADORA3ADORA2BLMNANT5E | |
| SCHEMBL1138803 | 0.85 | ADORA2A (0.60) | ADORA2AADORA3ADORA2BCYP2C19SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0640091-A4 | SYNTHESIS OF NUCLEOTIDE MONOMERS. | RIBOZYME PHARM INC (US) | 1995-07-26 | — | — | EP | claimed |
| EP-0640091-A1 | SYNTHESIS OF NUCLEOTIDE MONOMERS | RIBOZYME PHARMACEUTICALS, INC. (US) | 1995-03-01 | — | — | EP | claimed |
| WO-1993023413-A1 | SYNTHESIS OF NUCLEOTIDE MONOMERS | RIBOZYME PHARMACEUTICALS, INC. (US) | 1993-11-25 | — | — | WO | claimed |
| CN-118852302-B | Preparation method of compound | 天津兴博润生物制药有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-118852302-A | Preparation method of compound | 天津兴博润生物制药有限公司 | 2024-10-29 | — | — | CN | disclosed |
| EP-4367237-A2 | BIS-RNAI COMPOUNDS FOR CNS DELIVERY | Alnylam Pharmaceuticals, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| WO-2024073732-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20240092819-A1 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | SANOFI SA (FR) | 2024-03-21 | — | — | US | disclosed |
| CN-116981676-A | Cyano-protected riboguanosine phosphoramidites for reducing depyrimidition caused by alkylamine exposure during final deprotection | 安捷伦科技有限公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-4232455-A2 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | Sanofi (FR) | 2023-08-30 | — | — | EP | disclosed |
| CN-219307933-U | Evaporation separation device | 天津兴博润生物制药有限公司 | 2023-07-07 | — | — | CN | disclosed |
| EP-0640091-A4 | SYNTHESIS OF NUCLEOTIDE MONOMERS. | RIBOZYME PHARM INC (US) | 1995-07-26 | — | — | EP | disclosed |
| EP-0640091-A1 | SYNTHESIS OF NUCLEOTIDE MONOMERS | RIBOZYME PHARMACEUTICALS, INC. (US) | 1995-03-01 | — | — | EP | disclosed |
| WO-1993023413-A1 | SYNTHESIS OF NUCLEOTIDE MONOMERS | RIBOZYME PHARMACEUTICALS, INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| WO-1993003052-A1 | MULTIDOMAIN DNA LIGANDS FOR PROTEIN AND NUCLEIC ACID AFFINITY CHROMATOGRAPHY AND PROCESSING OF SOLID-PHASE DNA | ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 1993-02-18 | — | — | WO | disclosed |
| EP-0320103-A2 | Compounds for DNA deletion and oligomers used therefor as well as a method for use thereof | AJINOMOTO CO., INC. (JP) | 1989-06-14 | — | — | EP | disclosed |
| EP-0270651-A4 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES. | CALIFORNIA INST OF TECHN (US) | 1989-03-29 | — | — | EP | disclosed |
| EP-0270651-A1 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES. | CALIFORNIA INST OF TECHN (US) | 1988-06-15 | — | — | EP | disclosed |
| EP-0261552-A1 | Genetic engineering method to produce salmon calcitonin, and means to carry out this method | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-03-30 | — | — | EP | disclosed |
| WO-1988000201-A1 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES | CALIFORNIA INSTITUTE OF TECHNOLOGY, INC. (US) | 1988-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092819-A1 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | ASGR1, HAVCR2, SIGLEC7 | ADORA2A 97/4885ADORA3 68/4885ADORA2B 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.